COVID-19 Patients with Lymphocytopenia Are Likely to Suffer Severe Disease Symptoms
By LabMedica International staff writers Posted on 22 Jul 2020 |
Image: A scanning electron microscope image of normal circulating human blood showing red blood cells, several types of white blood cells including lymphocytes, a monocyte, a neutrophil and many small disc-shaped platelets (Photo courtesy of [U.S.] National Cancer Institute)
An easily recognizable feature in blood samples may be an indicator of whether a COVID-19 patient will be likely to suffer from a severe form of the disease.
Lymphocytopenia - abnormally low levels of white blood cells - is a common systemic manifestation of many viral illnesses; in particular, other coronaviruses like Severe Acute Respiratory Syndrome coronavirus (SARS‐CoV) and Middle Eastern Respiratory Syndrome coronavirus (MERS‐CoV) have been demonstrated to cause lymphocytopenia. However, few studies have examined whether lymphocytopenia found at the time of admission to the hospital is helpful in understanding the disease course.
For this reason, investigators at the University of Texas Health Science Center at Houston (USA) studied a cohort of hospital patients diagnosed with COVID‐19 to determine whether lymphocytopenia, found at the time of admission to the hospital, was associated with disease severity and other clinical outcomes.
For this study, the investigators analyzed blood samples obtained from 57 patients from a local Houston hospital. Results revealed that lymphocyte count was lower and lymphocytopenia more frequent in patients admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to those who were not. In addition, patients with lymphocytopenia were more likely to develop an acute kidney injury (AKI), a marker of organ failure, during admission.
The investigators integrated basic demographic, clinical, and laboratory data to formulate a theory explaining the relationship between lymphocytopenia at the time of hospital admission and clinical outcomes. Furthermore, they said that their findings supported the hypothesis that lymphocytopenia could be an early, useful, and easily obtained, prognostic factor in determining the clinical course and disease severity of a patient admitted to the hospital for COVID‐19.
“Because of the uncertainty surrounding the implications of this virus, we knew there needed to be a prognostic factor that could aid hospital workers in managing COVID-19,” said senior author Dr. Ahmad Farooq, assistant professor of gastroenterology at the University of Texas Health Science Center at Houston. “In this study, we discovered evidence of a relationship between lymphocytopenia and disease severity that could really help clinicians prepare for critically ill patients. The finding of an association with AKI warrants further research. Nevertheless, it is apparent here that lymphocytopenia may serve as a prognostic marker for AKI in patients with COVID-19.”
The link between lymphocytopenia and severity of COVID-19 infection was described in the July 10, 2020, online edition of the International Journal of Laboratory Hematology.
Related Links:
University of Texas Health Science Center at Houston
Lymphocytopenia - abnormally low levels of white blood cells - is a common systemic manifestation of many viral illnesses; in particular, other coronaviruses like Severe Acute Respiratory Syndrome coronavirus (SARS‐CoV) and Middle Eastern Respiratory Syndrome coronavirus (MERS‐CoV) have been demonstrated to cause lymphocytopenia. However, few studies have examined whether lymphocytopenia found at the time of admission to the hospital is helpful in understanding the disease course.
For this reason, investigators at the University of Texas Health Science Center at Houston (USA) studied a cohort of hospital patients diagnosed with COVID‐19 to determine whether lymphocytopenia, found at the time of admission to the hospital, was associated with disease severity and other clinical outcomes.
For this study, the investigators analyzed blood samples obtained from 57 patients from a local Houston hospital. Results revealed that lymphocyte count was lower and lymphocytopenia more frequent in patients admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to those who were not. In addition, patients with lymphocytopenia were more likely to develop an acute kidney injury (AKI), a marker of organ failure, during admission.
The investigators integrated basic demographic, clinical, and laboratory data to formulate a theory explaining the relationship between lymphocytopenia at the time of hospital admission and clinical outcomes. Furthermore, they said that their findings supported the hypothesis that lymphocytopenia could be an early, useful, and easily obtained, prognostic factor in determining the clinical course and disease severity of a patient admitted to the hospital for COVID‐19.
“Because of the uncertainty surrounding the implications of this virus, we knew there needed to be a prognostic factor that could aid hospital workers in managing COVID-19,” said senior author Dr. Ahmad Farooq, assistant professor of gastroenterology at the University of Texas Health Science Center at Houston. “In this study, we discovered evidence of a relationship between lymphocytopenia and disease severity that could really help clinicians prepare for critically ill patients. The finding of an association with AKI warrants further research. Nevertheless, it is apparent here that lymphocytopenia may serve as a prognostic marker for AKI in patients with COVID-19.”
The link between lymphocytopenia and severity of COVID-19 infection was described in the July 10, 2020, online edition of the International Journal of Laboratory Hematology.
Related Links:
University of Texas Health Science Center at Houston
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data